Genencor International and Gyros AB establish technology collaboration
Palo Alto, Calif. and Uppsala, Sweden, May 24, 2001 -Genencor International (Nasdaq: GCOR) and Gyros AB today announced the signing of an agreement to establish a one-year collaboration to apply the Gyros’ microfluidic technology to Genencor’s screening capabilities. The two companies will work together to design application-specific nano-scale microlaboratories in a compact disc (CD) format.
Under the terms of the agreement, Gyros will custom design applications and CDs specifically for Genencor’s screening assays. Genencor will serve as a technical evaluation site for Gyros’ prototype microfluidic robot and CDs. Gyros will benefit from the assistance of Genencor in the development of microfluidic assays applicable to research in a variety of industries.
Gyros’ proprietary technology platform offers Genencor the opportunity to accelerate biomaterial discovery and development programs by using a faster and higher throughput screen. In addition, the technology will increase the level of automation in proteomics and ultimately allow interfacing of the CDs to mass spectrometry.
“Our work with Gyros represents an advancement in the development of high-content, high information screening technology and is another example of how Genencor leverages its core technologies using cutting-edge avenues,” said Michael V. Arbige, senior vice president, technology of Genencor. “An ultimate goal with Gyros’ innovative screening capabilities is to enable interfacing of the technology to high throughput proteomics.”
The relationship builds off the highly advanced high throughput screening technology that is part of Genencor’s integrated i-biotech™ system and Gyros’ multi-disciplinary expertise in surface chemistry and microfluidic technology. Together, both companies intend to integrate their respective skills into the development of microlaboratory CDs for use in life science research, drug discovery and diagnostics.
“We are delighted to collaborate with an industry leader such as Genencor for their discovery and proteomics applications. Genencor’s perspective on implementation of novel technology will fit well with our approach to microfluidics and the flexibility of our platform design,” said Maris Hartmanis, chief executive officer of Gyros. “The ability to integrate a large number of laboratory processes and run hundreds of samples in parallel on a single, disposable CD will redesign traditional ways of working within proteomics.”
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: email@example.com / firstname.lastname@example.org
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.